Menu

Intellia Therapeutics, Inc. NTLA

Full chart Compare
Set alert

Price alert · NTLA

All alert types
11.35 USD +0.25 (+2.25%)

At closeNov 6, 2026, 7:26 PM EST

11.39 +0.04 +0.34%

After hours · Nov 6, 7:26 PM ET

11.02 Day range 11.40
8.04 52-week range 17.84
YTD
+26.25%
1 year
-7.87%

Revenue & Expenses

Other Income → Expenses: $28.30MOther Operating Income → Expenses: $15.92MExpenses → Selling, General & Admin: $119.80MExpenses → Research & Development: $388.86MGross Profit → Expenses: $51.75MRevenue → Gross Profit: $51.75MRevenue → Cost of Revenue: $15.92MNet Loss → Expenses: $412.69MOther Income$28.30MOther Operating Income$15.92MGross Profit$51.75MNet Loss$412.69MCost of Revenue$15.92MExpenses$508.66MSelling, General & Admin$119.80MResearch & Development$388.86MRevenue$67.67M

Latest period ending Dec 31, 2025 · select a line to chart its full history

NTLA annual income statement
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
67.67M57.88M36.27M52.12M33.05M
67.67M57.88M36.27M52.12M33.05M
-440.99M-534.26M-515.29M-458.16M-267.85M
-412.69M-519.02M-481.19M-474.19M-267.89M
-3.81-5.25-5.42-6.16-3.78
NTLA annual balance sheet
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
155.46M189.18M226.75M523.51M123.41M
842.13M1.19B1.30B1.52B1.29B
170.73M319.06M250.81M284.53M254.22M
93.33M210.20M115.35M130.70M74.02M
671.39M871.96M1.05B1.24B1.04B
NTLA annual cash flow
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
-394.74M-348.88M-394.09M-333.29M-225.03M
228.03M125.57M-31.35M160.31M-550.78M
131.49M185.75M130.32M582.96M736.69M
-1.13M-5.78M-13.98M-13.41M-12.76M
-35.22M-37.57M-295.11M409.98M-39.12M